Istaraatiijiyada Dhiirigelinta Novel waxay wanaajisaa badbaadada iyo waxtarka daawaynta CAR-T ee Leukemia Unug B ee Ba'an
Beijing, Shiinaha – Luulyo 23, 2024- Horumar la taaban karo, Isbitaalka Lu Daopei, oo kaashanaya Hebei Senlang Biotechnology, ayaa soo bandhigay natiijooyin rajo leh oo ka soo baxay daraasaddoodii ugu dambeysay ee ku saabsan daawaynta unugyada chimeric antigen receptor T (CAR-T). Daraasaddan, oo diiradda saareysa waxtarka iyo badbaadada unugyada CAR-T ee lagu farsameeyay dhiirrigeliyeyaal kala duwan, waxay calaamad u tahay horumar la taaban karo ee daaweynta soo noqoshada ama dib u soo noqoshada unugyada kansarka ee B unugga (B-ALL).
Daraasadda, oo cinwaankeedu yahay "Isticmaalka Dhiirrigeliyaha ee Habeeya Cufnaanta Dusha sare ee Molecules CAR waxay beddeli karaan Kinetics ee Unugyada CAR-T ee Vivo," waxay sahamisaa sida doorashada dhiirrigeliye ay saameyn ugu yeelan karto waxqabadka unugyada CAR-T. Cilmi-baarayaasha Jin-Yuan Ho, Lin Wang, Ying Liu, Min Ba, Junfang Yang, Xian Zhang, Dandan Chen, Peihua Lu, iyo Jianqiang Li oo ka socda Hebei Senlang Biotechnology iyo Lu Daopei Hospital ayaa hormuud ka ahaa cilmi baaristan.
Natiijooyinkoodu waxay muujinayaan in isticmaalka MND (myeloproliferative sarcoma virus MPSV enhancer, negative control region NCR deletion, d1587rev primer binding site beddelka) dhiirrigeliyaha unugyada CAR-T waxay keenaysaa cufnaanta dusha sare ee molecules CAR, taas oo iyana hoos u dhigaysa wax soo saarka cytokine. Tani waa mid muhiim ah sababtoo ah waxay kaa caawineysaa in la yareeyo dhibaatooyinka daran ee badanaa la xidhiidha daaweynta CAR-T, sida cytokine release syndrome (CRS) iyo CAR-T cell-related encephalopathy syndrome (CRES).
Tijaabada caafimaad, ee ka diiwaan gashan aqoonsiga ClinicalTrials.gov NCT03840317, waxaa ku jiray 14 bukaan oo loo qaybiyay laba kooxood: mid helaya unugyada CAR-T ee MND ay wado iyo kan kale oo helaya EF1A dhiirigeliyaha ay wado unugyada CAR-T. Waxaa cajiib ah, dhammaan bukaannada lagu daweeyay MND-ku-jiidheeyay unugyada CAR-T waxay heleen cafis dhammaystiran, iyadoo intooda badan ay muujiyeen xaalad cudur-xumo ah oo yar ka dib bishii ugu horreysay. Daraasadu waxay sidoo kale sheegtay in hoos u dhac yar oo ah CRS-da daran iyo CRES ee bukaanada lagu daweeyay MND-ku wado unugyada CAR-T marka la barbar dhigo kuwa lagu daweeyay unugyada EF1A.
Dr. Peihua Lu oo ka socda Isbitaalka Lu Daopei ayaa rajo ka muujiyay suurtagalnimada habkan cusub, isagoo leh, "Wadashaqeyntayada Hebei Senlang Biotechnology waxay keentay fikrado muhiim ah oo lagu hagaajinayo daaweynta unugyada CAR-T. Marka la hagaajiyo dhiirrigeliyaha, waxaan kor u qaadi karnaa astaanta badbaadada. ee daawaynta iyadoo la ilaalinayo waxtarkeeda
Daraasada waxaa lagu taageeray deeqo ka timid Aasaaska Sayniska Dabiiciga ah ee Gobolka Hebei iyo Waaxda Sayniska iyo Tignoolajiyada ee Gobolka Hebei. Waxay muujineysaa muhiimada xulashada dhiirigeliyaha ee horumarinta daawaynta unugyada CAR-T waxayna furaysaa dariiqyo cusub oo badbaado leh oo waxtar leh daaweynta kansarka.